N-乙酰基-DL-色氨酸钠 | 62307-74-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-乙酰基-DL-色氨酸钠
• CAS: 62307-74-8
• 化学式: C13H14N2NaO3
• 分子量: 269.25
• InChiKey: VZZUJVDCIBINIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.92
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  82.2
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

文献信息

• Compounds exhibiting thrombopoietin-like activities
  申请人：——

  公开号：US20030162724A1

  公开（公告）日：2003-08-28

  The compounds of the invention are compounds represented by the following general formula (1): 1 wherein E represents one selected from the group consisting of a methylidyne group and a nitrilo group, R 1 represents one selected from the group consisting of optionally substituted aryl groups and optionally substituted heteroaryl groups, R 2 represents one selected from the group consisting of a hydrogen atom and alkyl groups, W 1 represents an amino acid residue, A represents one selected from the group consisting of a carbonyl group and a sulfonyl group, X 1 represents one selected from the group consisting of optionally substituted alkylene groups and optionally substituted alkenylene groups, and p represents 0 or 1; and their pharmacologically acceptable salts, which exhibit thrombopoietin-like activity.

  本发明的化合物是由以下一般式（1）表示的化合物：其中E代表从甲基亚基团和硝基亚基团组成的群体中选择的一种，R1代表从可选择的取代芳基和可选择的取代杂环烷基组成的群体中选择的一种，R2代表从氢原子和烷基组成的群体中选择的一种，W1代表氨基酸残基，A代表从羰基和磺酰基组成的群体中选择的一种，X1代表从可选择的取代烷基烯基团和可选择的取代烯基烷基团组成的群体中选择的一种，p代表0或1；以及它们的药理学上可接受的盐，具有类似于血小板生成素的活性。
• [EN] PROTEIN COMPOSITIONS AND USE THEREOF<br/>[FR] COMPOSITIONS DE PROTÉINES ET LEUR UTILISATION
  申请人：DRUG DISCOVERY LAB AS

  公开号：WO2016103034A1

  公开（公告）日：2016-06-30

  The present invention relates to a method for stabilization of pharmaceutical formulation of proteins. In particular, the present invention relates to compositions and methods for stabilizing proteins via addition of methanesulphonic and/or meglumine and example, free from particles and/or microbubbles.

  本发明涉及一种稳定蛋白质制剂的方法。具体而言，本发明涉及通过添加甲磺酸甲酯和/或甲庆铵等物质来稳定蛋白质的组合物和方法，例如，不含颗粒和/或微泡。
• COATED PARTICLES, METHODS OF MAKING AND USING
  申请人：——

  公开号：US20040201117A1

  公开（公告）日：2004-10-14

  A particle coated with a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material includes an internal matrix core having at least one a nanostructured liquid phase, or at least on nanostructured liquid crystalline phase or a combination of the two is used for the delivery of active agents such as pharmaceuticals, nutrients, pesticides, etc. The coated particle can be fabricated by a variety of different techniques where the exterior coating is a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material

  涂覆有非层状材料（如非层状晶体材料、非层状非晶态材料或非层状半晶态材料）的粒子，包括具有至少一个纳米结构液相或至少一个纳米结构液晶相或两者的组合的内部基质核心，用于传递活性剂，如药物、营养素、杀虫剂等。涂覆的粒子可以通过各种不同的技术制造，其中外部涂层是非层状材料，如非层状晶体材料、非层状非晶态材料或非层状半晶态材料。
• Coated particles, methods of making and using
  申请人：——

  公开号：US20030108743A1

  公开（公告）日：2003-06-12

  A particle coated with a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material includes an internal matrix core having at least one a nanostructured liquid phase, or at least on nanostructured liquid crystalline phase or a combination of the two is used for the delivery of active agents such as pharmaceuticals, nutrients, pesticides, etc. The coated particle can be fabricated by a variety of different techniques where the exterior coating is a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material

  涂覆有非层状材料的颗粒，例如非层状晶体材料、非层状非晶材料或非层状半晶材料，包括至少一个纳米结构液相的内部基质核心，或至少一个纳米结构液晶相或两者的组合，用于传递活性物质，如药物、营养素、杀虫剂等。涂覆的颗粒可以通过各种不同的技术制造，其中外部涂层是非层状材料，例如非层状晶体材料、非层状非晶材料或非层状半晶材料。
• Pharmaceutical preparations for treatment of type II diabetes and methods for treatment of type II diabetes
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：US20040063780A1

  公开（公告）日：2004-04-01

  Pharmaceutical preparations for type II diabetes comprising as active ingredients thereof biguanide derivatives represented by the following general formula (1): 1 (where R 1 , R 2 and R 3 are the same or different and each represents one selected from the group consisting of hydrogen, optionally substituted lower alkyl groups and optionally substituted lower alkylthio groups), or their salts.

  治疗II型糖尿病的药物制剂，其包括下列一般式（1）所表示的双胍衍生物作为其活性成分：1（其中R1、R2和R3相同或不同，且每个代表从氢、可选择置换的较低烷基基团和可选择置换的较低烷基硫基基团组成的群中选择的一个），或其盐。